GlassScriptPhysician profile
Vijay Sharma
NPI 1356595268
$16,191.46
in general payments reported to CMS, 2019-2025
14 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $229 · 2021: $6,485 · 2022: $4,548 · 2023: $1,815 · 2024: $2,019 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $1,097 · Consulting Fee: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $1,096.87 |
| Consulting Fee | $204.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $13,236.22 | 2019-2025 | |
| Aerin Medical INC. | $1,223.70 | 2019-2025 | |
| Stryker Corporation | $768.91 | 2021-2025 | Fiagon Navigation Unit, Xpress Loprofile, Clarifix Cryotherapy Device |
| Medtronic, INC. | $269.96 | 2021-2023 | Stealthstation S8 Platform |
| Intersect Ent, INC. | $198.41 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2024 | Tezspire |
| Lilly USA, LLC | $65.32 | 2023 | Mounjaro |
| Smith+Nephew, INC. | $65.13 | 2019 | |
| Medtronic USA, INC. | $30.21 | 2019 | |
| Blue Earth Diagnostics | $27.45 | 2019 | |
| Karl Storz Endoscopy-America | $23.46 | 2020 | |
| Neurent Medical Limited | $16.50 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Paratek Pharmaceuticals, INC. | $16.20 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.